A Phase I/II Study of the Janus Kinase (JAK)1 and 2 Inhibitor Ruxolitinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia

导出原文传递

翻译打印收藏纠错

作者： Pemmaraju, Naveen ^[1] ; Kantarjian, Hagop ; Kadia, Tapan ; Cortes, Jorge ; Borthakur, Gautam ; Newberry, Kate ; Garcia-Manero, Guillermo ; Ravandi, Farhad ; Jabbour, Elias ; Dellasala, Sara ; Pierce, Sherry ; Verstovsek, Srdan

作者单位： Univ Texas Houston, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA ^[1]

关键词 Acute myelogenous leukemia Clinical study JAK2V617 mutation Janus kinase inhibitor Myelofibrosis Ruxolitinib

发布时间 2018-08-24

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Clinical lymphoma, myeloma & leukemia

2015年15卷3期

171-176页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

A Phase I/II Study of the Janus Kinase (JAK)1 and 2 Inhibitor Ruxolitinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Clinical lymphoma, myeloma & leukemia

相似文献

Clinical lymphoma, myeloma & leukemia

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

A Phase I/II Study of the Janus Kinase (JAK)1 and 2 Inhibitor Ruxolitinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Clinical lymphoma, myeloma & leukemia

相似文献

Clinical lymphoma, myeloma & leukemia

相关期刊

检索历史清除